Research
We are also exploiting the power of bioinformatics to identify novel mutations that drive the initiation and progression of brain tumors. Based on the CBTRUS 2006-2010 report, the overall average annual incidence rate for primary brain and CNS tumors was 21.04/100,000, 7.27/100,000 for malignant tumors. 68,184 individuals deceased between 2006-2010 due to malignant brain and central nervous system tumors. The same report estimated new cases for 2014 to be 66,240.
We have been able to translate various complementary cutting-edge genomic technologies, which were once solely research tools, to our clinical programs to analyze individual cancers. We can now gain comprehensive understanding of the molecular make-up of a cancer to pinpoint specific vulnerabilities and leverage these weak spots for precision treatments in our Recurrent Brain Tumor Treatment Program.